Subcutaneous Iron Octasaccharide Complexes for Companion Animal Anemia
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There are no safe and effective parenteral iron drugs specifically developed for the therapy of iron deficiency in companion animals, particularly dogs, with existing treatments being either subtherapeutic or associated with significant side effects and uncertainties regarding efficacy and safety.
Innovation Solution
Development of an iron oligoisomaltose or octasaccharide complex for subcutaneous administration, formulated as a ready-to-use injectable composition, providing a dose of 20 mg elemental iron per kg bodyweight, with specific molecular weight and dispersity ranges to ensure effective iron replenishment.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing parenteral iron drugs are used in companion animals, then iron deficiency can be treated, but significant side effects and uncertainties regarding efficacy and safety occur
Solution Approach 1:
The patent uses oligosaccharide complexes as intermediary carriers to deliver iron to companion animals. These complexes act as mediators between elemental iron and the animal's physiological systems, reducing direct toxicity while maintaining therapeutic efficacy. The oligosaccharide structure provides a biocompatible interface that mitigates harmful reactions.
Solution Approach 2:
The patent changes the chemical and physical parameters of iron delivery by using specific oligosaccharide molecular weights (850-1,150 Da), controlled dispersity (1.05-1.4), and specific monosaccharide unit distributions. These parameter changes transform iron from a potentially harmful element into a safe and effective therapeutic compound.
2Reliability
If existing iron treatments are administered, then some iron replenishment occurs, but subtherapeutic dosing limits effectiveness
Solution Approach 1:
The patent employs preliminary formulation work to create optimally dosed iron oligosaccharide complexes before administration. The iron is pre-complexed in therapeutically effective concentrations (100 mg/mL), ensuring that the full therapeutic dose can be delivered safely in a single subcutaneous injection without requiring prolonged subtherapeutic dosing.
3Productivity
If iron is administered to replenish stores rapidly, then hemoglobin concentration increases, but safety concerns arise with conventional formulations
Solution Approach 1:
The patent creates composite materials by combining iron with oligosaccharides in specific ratios and structures. This composite approach allows rapid iron delivery for quick hemoglobin repletion while the oligosaccharide matrix provides safety by controlling iron release and reducing direct tissue irritation.
Data Source
AI summary
The present invention relates to iron complex compounds for subcutaneous use in a method of therapy, e.g., for iron deficiency, particularly of iron deficiency anaemia, in a companion animal and to pharmaceutical compositions for subcutaneous administration, comprising an iron complex compound and a pharmaceutically acceptable carrier. The present invention relates more particularly, although not exclusively, to iron octasaccharide complexes, pharmaceutical compositions comprising an iron octasaccharide complex, and the iron octasaccharide complexes for use in a method of therapy of iron deficiency, particularly of iron deficiency anaemia, in a human or non-human subject.